Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial

Anne-Cathrine Vissing; E H Taudorf; C S Haak; P A Philipsen; Merete Hædersdal

doi:10.1111/jdv.13447

Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial

Anne-Cathrine Vissing, E H Taudorf, C S Haak, P A Philipsen, Merete Hædersdal

Department of Clinical Medicine

10 Citations (Scopus)

Abstract

BACKGROUND: Photoepilation is the treatment of choice for hair removal in patients with hirsutism, but it remains a challenge to prevent regrowth of hairs.

OBJECTIVES: The objective of this study was to investigate whether topical eflornithine maintains hair reduction in hirsute patients after cessation of intense pulsed light (IPL) therapy.

METHODS: A randomized, split-face, single-blinded controlled trial on topical eflornithine vs. no eflornithine treatment (control) after 5-6 IPL-treatments in 22 women with facial hirsutism. Application of eflornithine was initiated after the final IPL-treatment (baseline) and applied twice daily for 6 months to half of the face. Patients were assessed at baseline and 1, 3 and 6 months after the final IPL-treatment. The primary endpoint was difference in facial hair counts between eflornithine vs. no treatment. Secondary endpoints were patient-evaluated efficacy, patient satisfaction and safety.

RESULTS: A total of 18 patients completed the study protocol. At 1 month after final IPL-treatment, eflornithine reduced hair regrowth by 14% (P = 0.007, n = 20 patients), at 3 months by 9% (P = 0.107, n = 19) and at 6 months by 17% (P = 0.048, n = 18) compared to no treatment. Patient-evaluated efficacy supported blinded hair counts and patients were satisfied with eflornithine treatment throughout the study (median VAS 5-6). Eflornithine was generally well tolerated, but blinded evaluation demonstrated deterioration of acne in two patients at final assessment.

CONCLUSION: Topical eflornithine provides a self-administered treatment with a potential to maintain IPL-induced hair reduction in hirsute patients.

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology : JEADV
Volume	30
Issue number	2
Pages (from-to)	314-319
Number of pages	6
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.13447
Publication status	Published - 1 Feb 2016

Keywords

Administration, Topical
Adolescent
Adult
Dose-Response Relationship, Drug
Eflornithine
Face
Female
Follow-Up Studies
Hair Removal
Hirsutism
Humans
Intense Pulsed Light Therapy
Middle Aged
Ornithine Decarboxylase Inhibitors
Patient Satisfaction
Single-Blind Method
Treatment Outcome
Young Adult
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Access to Document

10.1111/jdv.13447

Cite this

Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial. / Vissing, Anne-Cathrine; Taudorf, E H; Haak, C S et al.
In: Journal of the European Academy of Dermatology and Venereology : JEADV, Vol. 30, No. 2, 01.02.2016, p. 314-319.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{0637e4dfcc894ee3855fed3e4624a59f,

title = "Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial",

abstract = "BACKGROUND: Photoepilation is the treatment of choice for hair removal in patients with hirsutism, but it remains a challenge to prevent regrowth of hairs.OBJECTIVES: The objective of this study was to investigate whether topical eflornithine maintains hair reduction in hirsute patients after cessation of intense pulsed light (IPL) therapy.METHODS: A randomized, split-face, single-blinded controlled trial on topical eflornithine vs. no eflornithine treatment (control) after 5-6 IPL-treatments in 22 women with facial hirsutism. Application of eflornithine was initiated after the final IPL-treatment (baseline) and applied twice daily for 6 months to half of the face. Patients were assessed at baseline and 1, 3 and 6 months after the final IPL-treatment. The primary endpoint was difference in facial hair counts between eflornithine vs. no treatment. Secondary endpoints were patient-evaluated efficacy, patient satisfaction and safety.RESULTS: A total of 18 patients completed the study protocol. At 1 month after final IPL-treatment, eflornithine reduced hair regrowth by 14% (P = 0.007, n = 20 patients), at 3 months by 9% (P = 0.107, n = 19) and at 6 months by 17% (P = 0.048, n = 18) compared to no treatment. Patient-evaluated efficacy supported blinded hair counts and patients were satisfied with eflornithine treatment throughout the study (median VAS 5-6). Eflornithine was generally well tolerated, but blinded evaluation demonstrated deterioration of acne in two patients at final assessment.CONCLUSION: Topical eflornithine provides a self-administered treatment with a potential to maintain IPL-induced hair reduction in hirsute patients.",

keywords = "Administration, Topical, Adolescent, Adult, Dose-Response Relationship, Drug, Eflornithine, Face, Female, Follow-Up Studies, Hair Removal, Hirsutism, Humans, Intense Pulsed Light Therapy, Middle Aged, Ornithine Decarboxylase Inhibitors, Patient Satisfaction, Single-Blind Method, Treatment Outcome, Young Adult, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't",

author = "Anne-Cathrine Vissing and Taudorf, {E H} and Haak, {C S} and Philipsen, {P A} and Merete H{\ae}dersdal",

note = "{\textcopyright} 2015 European Academy of Dermatology and Venereology.",

year = "2016",

month = feb,

day = "1",

doi = "10.1111/jdv.13447",

language = "English",

volume = "30",

pages = "314--319",

journal = "Journal of the European Academy of Dermatology and Venereology : JEADV",

issn = "0926-9959",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism

T2 - a randomized controlled trial

AU - Vissing, Anne-Cathrine

AU - Taudorf, E H

AU - Haak, C S

AU - Philipsen, P A

AU - Hædersdal, Merete

PY - 2016/2/1

Y1 - 2016/2/1

N2 - BACKGROUND: Photoepilation is the treatment of choice for hair removal in patients with hirsutism, but it remains a challenge to prevent regrowth of hairs.OBJECTIVES: The objective of this study was to investigate whether topical eflornithine maintains hair reduction in hirsute patients after cessation of intense pulsed light (IPL) therapy.METHODS: A randomized, split-face, single-blinded controlled trial on topical eflornithine vs. no eflornithine treatment (control) after 5-6 IPL-treatments in 22 women with facial hirsutism. Application of eflornithine was initiated after the final IPL-treatment (baseline) and applied twice daily for 6 months to half of the face. Patients were assessed at baseline and 1, 3 and 6 months after the final IPL-treatment. The primary endpoint was difference in facial hair counts between eflornithine vs. no treatment. Secondary endpoints were patient-evaluated efficacy, patient satisfaction and safety.RESULTS: A total of 18 patients completed the study protocol. At 1 month after final IPL-treatment, eflornithine reduced hair regrowth by 14% (P = 0.007, n = 20 patients), at 3 months by 9% (P = 0.107, n = 19) and at 6 months by 17% (P = 0.048, n = 18) compared to no treatment. Patient-evaluated efficacy supported blinded hair counts and patients were satisfied with eflornithine treatment throughout the study (median VAS 5-6). Eflornithine was generally well tolerated, but blinded evaluation demonstrated deterioration of acne in two patients at final assessment.CONCLUSION: Topical eflornithine provides a self-administered treatment with a potential to maintain IPL-induced hair reduction in hirsute patients.

AB - BACKGROUND: Photoepilation is the treatment of choice for hair removal in patients with hirsutism, but it remains a challenge to prevent regrowth of hairs.OBJECTIVES: The objective of this study was to investigate whether topical eflornithine maintains hair reduction in hirsute patients after cessation of intense pulsed light (IPL) therapy.METHODS: A randomized, split-face, single-blinded controlled trial on topical eflornithine vs. no eflornithine treatment (control) after 5-6 IPL-treatments in 22 women with facial hirsutism. Application of eflornithine was initiated after the final IPL-treatment (baseline) and applied twice daily for 6 months to half of the face. Patients were assessed at baseline and 1, 3 and 6 months after the final IPL-treatment. The primary endpoint was difference in facial hair counts between eflornithine vs. no treatment. Secondary endpoints were patient-evaluated efficacy, patient satisfaction and safety.RESULTS: A total of 18 patients completed the study protocol. At 1 month after final IPL-treatment, eflornithine reduced hair regrowth by 14% (P = 0.007, n = 20 patients), at 3 months by 9% (P = 0.107, n = 19) and at 6 months by 17% (P = 0.048, n = 18) compared to no treatment. Patient-evaluated efficacy supported blinded hair counts and patients were satisfied with eflornithine treatment throughout the study (median VAS 5-6). Eflornithine was generally well tolerated, but blinded evaluation demonstrated deterioration of acne in two patients at final assessment.CONCLUSION: Topical eflornithine provides a self-administered treatment with a potential to maintain IPL-induced hair reduction in hirsute patients.

KW - Administration, Topical

KW - Adolescent

KW - Adult

KW - Dose-Response Relationship, Drug

KW - Eflornithine

KW - Face

KW - Female

KW - Follow-Up Studies

KW - Hair Removal

KW - Hirsutism

KW - Humans

KW - Intense Pulsed Light Therapy

KW - Middle Aged

KW - Ornithine Decarboxylase Inhibitors

KW - Patient Satisfaction

KW - Single-Blind Method

KW - Treatment Outcome

KW - Young Adult

KW - Journal Article

KW - Randomized Controlled Trial

KW - Research Support, Non-U.S. Gov't

U2 - 10.1111/jdv.13447

DO - 10.1111/jdv.13447

M3 - Journal article

C2 - 26507926

SN - 0926-9959

VL - 30

SP - 314

EP - 319

JO - Journal of the European Academy of Dermatology and Venereology : JEADV

JF - Journal of the European Academy of Dermatology and Venereology : JEADV

IS - 2

ER -

Adjuvant eflornithine to maintain IPL-induced hair reduction in women with facial hirsutism: a randomized controlled trial

Abstract

Keywords

Access to Document

Fingerprint

Cite this